Lung Cancer Trials Ask AI to find trials
TerminatedNot applicableNCT00585117
Official study title

Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients

Study summary

Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the basis for quantitative in vivo tumor imaging by Cu-61 diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue hypoxia. We hypothesize that the hypoxia levels are predictive of the tumor response to therapy. Patients will have 2 CU-ATSM PET scans done and the goal is to show spatially stable tracer distributions that correlate with tumor hypoxia. This study will serve as a pilot study for a PO1 submission

Ask AI to explain this study
Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedPET-imaging with CuATSM and PET Imaging

Plus 4 other study approaches.

Who it may be forCNS Brain Metastases · Head and Neck Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 13, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?University of Wisconsin, Madison

Study sponsor

01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Not applicable
Sponsor
University of Wisconsin, Madison
Interventions being studied
Procedure: PET-imaging with CuATSM; Procedure: PET Imaging; Procedure: PET CuATSM; Procedure: PET imaging; Procedure: PET imaging with CuATSM; Procedure: PET imaging with CuATSM
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Study topics
Brain metastases→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Able to tolerated a PET/CT scan
  • Age 18 or older
  • Patient being considered for XRT for treatment of their cancer
  • Able to provide written informed consent
Reasons someone may not be able to joinExclusion criteria
  • severe claustrophobia or inability to tolerate the PET scan
  • pregnant or breastfeeding women
  • Patients that need supplemental oxygen
  • Patients enrolled in experimental treatments

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of Wisconsin Hospital and ClinicsMadison, Wisconsin

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 13, 2019. Always confirm current availability with the study team.

View original record ↗